Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Recurrent/Metastatic Gastric Cancer Clinical Trial

Official title:
An Open-label, Multicenter Phase Ib/II Study of Ramucirumab in Combination With Trastuzumab and Weekly Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer

Status Active, not recruiting

Clinical Trial Summary

Human epidermal growth factor receptor 2 (HER2) is overexpressed or amplified in 10-20% of gastric or gastroesophageal junction cancer. Trastuzumab combined with fluorouracil and platinum has been established as first-line treatment for patients with HER2-positive gastric cancer. The role of trastuzumab in second-line treatment for HER2-positive gastric cancer has not yet been addressed. Here, we evaluated the safety and efficacy of adding trastuzumab to ramucirumab and paclitaxel combination as a second-line treatment in HER2-positive gastric cancer progressed after trastuzumab-containing chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Recurrent/Metastatic Gastric Cancer
Stomach Neoplasms

Clinical Trial Details

NCT number	NCT04888663
Study type	Interventional
Source	Yonsei University
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	February 13, 2018
Completion date	September 2, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04835896` - Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer	Phase 1/Phase 2
	Completed	`NCT05535569` - Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer	Phase 1/Phase 2